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Background: In colorectal cancer (CRC), tumour budding at the invasion front is associated with lymph node (LN) and distant
metastasis. Interestingly, tumour budding can also be detected in biopsies (intratumoural budding; ITB) and may have similar
clinical importance. Here we investigate whether ITB in preoperative CRC biopsies can be translated into daily diagnostic practice.
Methods: Preoperative biopsies from 133 CRC patients (no neoadjuvant therapy) underwent immunohistochemistry for pan-
cytokeratin marker AE1/AE3. Across all biopsies for each patient, the densest region of buds at  40 (high-power field; HPF) was
identified and buds were counted.
Results: A greater number of tumour buds in the biopsy was associated with pT stage (P¼ 0.0143), LN metastasis (P¼ 0.0007),
lymphatic (P¼ 0.0065) and venous vessel invasion (P¼ 0.0318) and distant metastasis (cM1) (P¼ 0.0013). Using logistic regression,
a ‘scale’ was developed to estimate the probability of LN and distant metastasis using the number of tumour buds (e.g. 10 buds
per HPF: 64% chance of LN metastasis; 30 buds per HPF: 86% chance). Inter-observer agreement for ITB was excellent (intraclass
correlation coefficient: 0.813).
Conclusion: Tumour budding can be assessed in the preoperative biopsy of CRC patients. It is practical, reproducible and
predictive of LN and distant metastasis. Intratumoural budding qualifies for further investigation in the prospective setting.
The preoperative management of colorectal cancer (CRC) is
based on an interdisciplinary collaboration between oncologists,
gastroenterologists, surgeons, radiologists and pathologists.
Indeed, rectal cancer patients with an advanced T stage (cT3
or cT4) and/or presence of lymph node (LN) metastases (Nþ )
are typically selected for neoadjuvant therapy (Schmoll et al,
2012). In the preoperative setting, the pathologist’s role is
limited to the confirmation of a diagnosis of malignancy from
the preoperative biopsy as the neoplastic nature of the lesion is
already highly suspected from the clinical point of view.
Although many histomorphological parameters such as tumour
grade, lymphatic and vascular invasion, tumour border config-
uration, perineural infiltration, intra- and peritumoural inflam-
mation and histological subtype should be reported in the daily
practice (Bosman et al, 2010), their use is limited to the
resection; consequently, these features do not influence
the preoperative management of the patient as they cannot be
applied to biopsies.
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Over the last years, a novel and promising histomorphological
parameter, namely ‘tumour budding’ has been reported in many
studies (Okuyama et al, 2002; Ueno et al, 2002; Okuyama et al,
2003; Tanaka et al, 2003; Ueno et al, 2004; Nakamura et al, 2005;
Park et al, 2005; Prall et al, 2005; Wang et al, 2009). Tumour
budding is defined as the presence of single tumour cells or small
tumour cell clusters of up to five cells at the invasive front of CRC.
The presence of tumour budding is associated with LN and distant
metastases as well as worse survival, independently of the applied
scoring system (Okuyama et al, 2002; Ueno et al, 2002, 2004;
Okuyama et al, 2003; Tanaka et al, 2003; Nakamura et al, 2005;
Park et al, 2005; Prall et al, 2005; Wang et al, 2009). In 1989,
Morodomi et al (1989) described the presence of budding in
biopsies from rectal cancer patients and its strong association with
lymphatic invasion and LN metastasis. In 2011, influenced by the
promising prognostic parameters intratumoural and peritumoural
lymphocytic infiltration in CRC, we systematically analysed whole-
tissue sections from the surgical resection and the presence of
tumour budding within the whole tumour mass and introduced the
terms intratumoural (ITB) and peritumoural (PTB) budding to
characterise the location of tumour buds either within the tumour
centre or at the invasion front of CRC, respectively (Lugli et al,
2011). The promising diagnostic power of ITB in preoperative
biopsies of colon and rectal cancers was recently confirmed by
two studies with 72 and 89 patients (Giger et al, 2012; Rogers
et al, 2014).
The aim of the present study was to investigate on a cohort of
colon and rectal cancer patients not receiving neoadjuvant therapy
(N¼ 133) and with full histopathological data whether ITB in
preoperative biopsies can be translated into daily diagnostic
practice. To this end, we use well-established methods, namely
immunohistochemistry (pan-cytokeratin marker) to optimally
visualise tumour buds and a high-power field method of scoring,
which is already used to count mitoses in breast cancer, sarcomas
and gastrointestinal stromal tumours.
MATERIALS AND METHODS
Patients. All patients with primary CRC surgically treated
between 2002 and 2011 at the University Hospital Insel, Bern,
Switzerland were initially entered into this study. Three hundred
and forty-six patients were identified. Of these, 185 had a matched
preoperative diagnostic biopsy available. For these 185 cases,
Hematoxylin and Eosin (H&E) slides from surgical resections were
reviewed by one experienced gastrointestinal pathologist (AL) and
two residents-in-training (HD and VK), blinded to findings from
the preoperative biopsy. The following histopathological para-
meters were revised: TNM (7th edition), histological subtype,
tumour grade, lymphatic invasion (L), venous invasion (V),
number of tumour deposits, perineural invasion (Pn), the number
of LNs harvested and regression grade according to the College of
American Pathologists (CAP) for patients preoperatively treated
with radio and/or chemotherapy. All cases were grossed according
to the national guidelines on quality assurance provided by the
Swiss Society of Pathology: All loco-regional LNs were macro-
scopically identified by careful and meticulous examination of the
pericolonic fat. Lymph nodes with a diameter below 0.5 cm were
embedded completely and examined on H&E. Nodes with a
diameter between 0.5 and 0.7 cm were bisected and nodes greater
than 0.7 cm in diameter were sectioned at 0.2 cm intervals and
embedded completely. Clinical data were obtained from patient
records and included age at diagnosis, gender, tumour location,
clinical TNM staging, neoadjuvant and adjuvant therapy informa-
tion. Clinical staging was performed primarily by computer
tomography (CT) (including PET-CT) followed by magnetic
resonance imaging (MRI) and ultrasound. Thirty patients receiving
neoadjuvant or preoperative therapy were excluded from further
analysis. Histopathological re-review of the preoperative biopsies
was also undertaken. In addition, information on the number of
biopsies per patient and the number of biopsies containing tumour
was determined.
Assay methods. All biopsies were fixed in 10% buffered formalin,
paraffin-embedded and archived at the Institute of Pathology,
University of Bern, Switzerland. Tumour blocks were retrieved and
sectioned at 4 mm. An immunohistochemistry double-stain for
pan-cytokeratin marker AE1/AE3 (Dako, Glostrup, Denmark,
mouse monoclonal, 1 1 : 200, enzyme pretreatment 5min; DAB
chromogen;) and CD8þ (Dako C8/144B, 1 : 100, pretreatment
with Tris buffer, at 951 for 20min; AEC chromogen) using an
automated Leica Bond III instrument and counterstained with
Hematoxylin was performed. Pan-cytokeratin staining was used to
evaluate tumour buds. This study was approved by the local ethics
committee of the Insel Hospital (16 March 2012).
Assessment of tumour budding. Tumour budding was assessed
using the following method. All biopsies from a single patient were
scanned and those containing tumour were evaluated. One single
tumour hot-spot containing the greatest density of tumour buds
(Nikon Eclipse 50i microscope at  40 magnification, field area
0.1963mm2) upon pan-cytokeratin AE1/AE3 staining was identi-
fied and the number of tumour buds was counted and recorded.
Tumour buds were defined as single tumour cell of clusters of up to
five cells or single tumour cells with a defined nucleus and diffuse
cytoplasmic staining for AE1/AE3 (Figure 1). Tumour budding
counts from two independent observers (AL and HD) were utilised
to determine the inter-observer agreement of the scoring method.
Study design. The study design is outlined in Figure 2. Of the 346
patients initially identified as having surgical treatment for primary
CRC from 2002 to 2011, 185 had matched biopsies. Of these,
23 patients were further excluded as they received a preoperative
radio/or chemotherapy. Immunohistochemistry was performed on
the remaining cases and were scored for tumour budding using the
hot-spot method. Upon re-review of stained biopsies, 29 cases were
further excluded since, due to sectioning of the biopsy, only few
tumour cells remained for evaluation. The final number of
Figure 1. Assessment of intratumoural budding. Preoperative colonic
biopsy stained for pan-cytokeratin (brown) to highlight single tumour
buds. The densest area (hot-spot) of intratumoural budding is
identified. At  40 magnification, the total number of tumour buds in
one single HPF is counted. The full colour version of this figure is
available at British Journal of Cancer online.
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matched preoperative biopsies with tumour budding scores and
completely re-reviewed surgical resections was 133. Patient
characteristics are listed in Table 1.
Statistics. The non-parametric Wilcoxon Rank Sum or Kruskal–
Wallis test was used to compare ranks of tumour budding scores
for categorical variables. For age and total LNs collected, the
estimate for tumour buds from the linear regression model was
used. The inter-observer agreement was determined using the
intraclass correlation coefficient (ICC), with values approaching
1.0 indicating improved agreement. Logistic regression analysis
was performed to calculate the probability of LN metastasis and
distant metastasis as a function of the number of tumour buds in
the biopsy. Briefly, the probability P¼ e(boþ b1x)/(1 e(boþ b1x)),
where bo and b1 are estimates of the logistic equation and x is the
number of tumour buds. In addition, odds ratios (ORs) and 95%
confidence intervals (CI) were used to determine the effect of
tumour budding on each significant variable. The area under the
ROC curve (AUC) was used to determine the discriminatory
ability of budding for the feature.
RESULTS
Tumour budding in the biopsy. An average of 12 tumour buds
per hot-spot was found with a median of five buds. Ninety percent
of all cases showed o25 buds per hot-spot. In more detail,
97 patients had between 0 and 10 buds, 19 had 11–20 buds, 7 had
21–30 buds and 6 had 31–50 buds per hot-spot. Only four cases
had 450 buds per hot-spot and all four were of signet ring cell
histology. The inter-observer assessment was performed on 133
cases. The ICC was 0.801 indicating excellent agreement between
independent observers. All cases with450 buds per hot-spot were
removed and again assessed for agreement. The ICC was 0.72
indicating strong agreement.
Tumour budding in the biopsy and clinicopathological features.
The association between a greater number of tumour buds in the
biopsy and both clinical and histopathological features of the
surgical resection is outlined in Table 2. A greater number of
All patients with primary
colorectal cancer 2002-2011
(n = 346)
Patients with matched preoperative
biopsy + resection available
(n = 185)
Final cohort
(n = 133)
Case re-review
Immunohistochemistry of biospsy (pan-cytokeratin)
No matched preoperative
biopsy available
Preoperative therapy
Unevaluable biopsy
Figure 2. Study design. Out of an initial cohort of 346 patients,
matched preoperative biopsies were available for 185. Cases were
re-reviewed. Patients receiving preoperative therapy were further
excluded. Biopsies underwent immunohistochemistry and the final
number of evaluable cases was 133.
Table 1. Characteristics of patients with preoperative biopsy and
matched oncosurgical resection (N¼ 133)
N (%)
Age (years)
Median (min, max) 72.2 (30–91)
Gender
Male 79 (59.4)
Female 54 (40.6)
Histological subtype
Non-mucinous 107 (81.1)
Mucinous 25 (18.9)
Tumour location
Left 42 (31.8)
Rectum 31 (23.5)
Right 59 (44.7)
pT
pT1 10 (7.5)
pT2 22 (16.5)
pT3 71 (53.4)
pT4 30 (22.6)
pN
pN0 56 (42.1)
pN1–2 77 (57.9)
No. lymph nodes collected
Median (min, max) 22 (4–73)
Tumour deposits
0 94 (84.7)
1 12 (10.8)
41 5 (3.5)
Metastasis
cM0 88 (69.3)
cM1 39 (30.7)
Lymphatic invasion
L0 30 (25.9)
L1 86 (74.1)
Venous invasion
V0 58 (49.6)
V1–2 59 (51.4)
Perineural invasion (Pn)
0 101 (88.6)
1 13 (11.4)
Tumour grade
G1–2 90 (65.4)
G3 46 (34.6)
Adjuvant therapy
None 89 (67.9)
Yes 42 (62.1)
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tumour buds in the biopsy was significantly associated with a more
advanced pT stage (P¼ 0.0143), LN metastasis (P¼ 0.0007),
lymphatic vessel invasion (P¼ 0.0065) and venous vessel invasion
(P¼ 0.0318) as determined from the surgical specimen.
Additionally, a greater number of buds was observed in patients
with distant metastasis (cM1) (P¼ 0.0013).
Next, using the logistic regression equation, a probability scale
was derived for predicting the risk of (A) LN metastasis and (B)
distant metastasis as a function of the number of tumour buds
(Figure 3). The estimates for the intercept and number of buds
were  0.1865 and 0.0602. The greater the number of tumour
buds, the greater the probability for local and distant metastasis.
For example, a patient with a biopsy containing 10 tumour buds
would have a 64% chance of LN metastasis, whereas the probability
increases in a patient with 30 buds or 450 buds (i.e., signet ring
cell tumour) to 86% and 95%, respectively. Similarly, a patient with
10 buds in the preoperative biopsy has a low probability of distant
metastasis (30%) in comparison with a patient with 30 or 50 buds
(53% and 75%, respectively).
DISCUSSION
The present study demonstrates that the presence of ITB in colon
and rectal cancer biopsies (not treated with neoadjuvant therapy) is
associated with higher T stage (P¼ 0.0143), lymphatic (P¼ 0.007)
and vascular invasion (P¼ 0.032), LN (P¼ 0.001) and distant
metastases (P¼ 0.001). The results underline the diagnostic
importance of ITB and are in line with the results from the
literature (Morodomi et al, 1989; Lugli et al, 2011; Giger et al, 2012;
Rogers et al, 2014). The practical approach to ITB is user-friendly,
concise and understandable, three characteristics that are impor-
tant for the translation of a histopathological biomarker into daily
diagnostic practice.
Morodomi et al (1989) previously showed in 1989 the
correlation of budding in preoperative biopsies and the presence
of LN metastases in 112 rectal cancer patients. These findings were
confirmed by Giger et al (2012) analysing preoperative biopsies
and the corresponding resections of 72 CRC patients; Rogers et al
(2014) additionally underlined the predictive power of ITB for
nodal metastases in 89 rectal cancer patients treated with
neoadjuvant therapy. Both Giger and Rogers relied on HE-stained
sections of the preoperative biopsy and used a semi-quantitative,
three-tiered scoring system. In 2011, our research group system-
atically analysed the presence of budding on 511 whole-tissue
sections after pan-cytokeratin staining of CRC which resulted in
the concept of stratifying tumour budding into ITB and PTB (Lugli
et al, 2011). In fact the presence of tumour budding in preoperative
biopsies (ITB) and in corresponding resections (PTB) is strongly
and positively correlated suggesting that an overall tumour
budding (OTB) count could be useful. We further showed that
ITB was an independent prognostic factor. In summary, all these
studies highlight the diagnostic, prognostic and predictive potential
of ITB.
Strong points of the present study include the selection of the
biomarker and the practical approach. Tumour budding is a robust
histomorphological marker and declared an independent prog-
nostic factor by many different studies, independently of the
selected scoring system (Hase et al, 1993; Okuyama et al, 2002,
2003; Ueno et al, 2002, 2004; Jass et al, 2003; Nakamura et al, 2005;
Park et al, 2005; Horkko et al, 2006; Choi et al, 2007; Lugli et al,
2009; Wang et al, 2009). These results are biologically not
surprising as tumour buds likely represent an epithelial-mesench-
ymal transition (EMT)-like process, express proteins of tumour
aggressiveness such as matrix-metalloproteinases, nuclear b-
catenin, VEGF, p16 and some potential stem cell markers in
association with loss of adhesion molecules such as E-cadherin
(Zlobec and Lugli, 2010). Interestingly, tumour budding is
completely independent of tumour grade (defined as the
percentage of glandular formation), tumour border configuration
Table 2. Association of budding in the preoperative biopsy (median
number of buds) and clinicopathological features of the resected
specimen in patients not treated with neoadjuvant therapy (N¼ 133)
ITB
median P-value OR (95% CI) AUC
Age (years)
Correlation coeff 0.04 0.6622
Gender
Male 5.0 0.2843
Female 5.5
Histological subtype
Non-mucinous 5.0 0.2052
Mucinous 6.0
Tumour location
Left 4.0 0.1372
Rectum 5.0
Right 6.0
pT
pT1þpT2 3.5 0.0143 1.09 (1.014–1.23) 0.644
pT3þpT4 5.0
pN
pN0 3.5 0.0007 1.062 (1.014–1.112) 0.672
pN1–2 6.0
No. lymph nodes collected
Correlation coeff 0.099 0.2549
Tumour deposits
0 5.0 0.8695
1 or more 6.0
Metastasis
cM0 4.0 0.0013 1.05 (1.014–1.087) 0.678
cM1 8.0
Lymphatic invasion
L0 3.5 0.0065 1.117 (1.025–1.216) 0.667
L1 6.0
Venous invasion
V0 5.0 0.0318 1.054 (1.011–1.1) 0.617
V1–2 5.5
Perineural invasion (Pn)
0 5.0 0.1726
1 11.0
Tumour grade
G1–2 5.0 0.1446
G3 6.0
Abbreviations: AUC¼ area under the ROC curve; CI¼ confidence interval;
coeff¼ coefficient; ITB¼ intratumoural budding; OR¼odds ratio.
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and molecular features such as mismatch-repair status, CpG Island
Methylator Phenotype (CIMP), KRAS and BRAF mutation status
(Zlobec et al, 2012a). The main reason why tumour budding is not
completely integrated in the pathology reports is the lack of a
standardized scoring system, although, as stated above, the
prognostic power seems to be independent of the applied scoring
system (Horcic et al, 2013). In this study, we selected a practical
approach including two steps: first, the pathologist needs to
optimally visualise buds in the preoperative biopsies by using
immunohistochemistry (pan-cytokeratin marker), as buds cannot
be easily recognised in areas of inflammation. The argument that
the use of one single immunostaining is cost-ineffective is not valid
as lymphoma, sarcoma and breast cancer diagnostics are based on
many immmunohistochemical markers. Second, pathologists are
already familiar with counting mitoses and cells in high-power
field (HPF) such as in GISTs, lymphomas, sarcomas and breast
cancer (BRE score).
On the basis of the actual number of tumour buds, a predictive
scale for LN and distant metastasis was constructed. The actual
probability for both outcomes could therefore be visualised. Such
an approach has the distinct advantage of not relying on a cutoff
score for low- or high-grade budding, which will ease the diagnosis
of ITB for pathologists as well as the interpretation of the findings
for all members of the interdisciplinary team. For the actual
number of buds the corresponding probabilities can be determined
thereby giving ‘relativity’ to the findings. Moreover, we show that
the inter-observer agreement of ITB is strong using the hot-spot
method, again underlining the advantage of this approach.
There are at least three scenarios where ITB detected from
preoperative biopsies may have clinical relevance. The first is in
patients with clinical stage II rectal cancers. Although most
patients with stage II tumours are offered a neoadjuvant therapy,
the presence of ITB in the pretreatment biopsy is an estimator
of tumour behaviour that may help to stratify patients into high-
and low-risk groups. The second may be in the preoperative
management of patients with clinical stage II colon cancers.
Although these cancers are not typically treated in the
neoadjuvant setting, evidence from the recent pilot phase of the
FOXTROT trial for locally advanced colon cancer patients shows
the feasibility and possible survival benefit of preoperative
chemotherapy (Foxtrot Collaborative G, 2012). Intratumoural
budding may help to identify patients with stage II cancers who
are at high-risk for nodal metastasis, who may be candidates for
neoadjuvant chemotherapy. The third is in patients with
submucosally invasive (T1) CRCs after endoscopic resection that
may be at high-risk of LN positivity, and thus would benefit from
consequent surgical resection. In this context, at least a dozen
studies (reviewed in (Zlobec et al, 2012b)) have shown that
tumour budding detected in the surgical resection specimen
predicts the future development of LN positivity in these early T1
cancers.
One weakness of our study is the sample size (especially the
number of rectal cancer cases). However, in addition to the already
published results in the literature and considering the fact that also
in colon cancer ITB will have an important role in the preoperative
management, the weakness may be considered marginal. In fact,
this appears to be the largest study to date to evaluate ITB in
preoperative biopsies.
In conclusion, our results highlight ITB as a histomorphological
parameter in preoperative biopsies of colon and rectal cancer
patients. This study together with previous works has laid a solid
retrospective foundation for future large prospective studies.
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